Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with Oxaliplatin and S-1 in Advanced Hepatoid Adenocarcinoma of the Stomach
NCT04863430Phase 2Withdrawn
- Sponsor
- Peking University
- Start
- May 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Hepatoid adenocarcinoma of the stomach (HAS), sponsored by Peking University. Primary endpoint: Objective Response Rate at 2 years. Planned start May 2021; status: withdrawn.
02
Drugs
Rivoceranib
03
Conditions
Hepatoid adenocarcinoma of the stomach (HAS)
Beyond the preview
Go deeper on NCT04863430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863430.